Trial Profile
A Phase III Study of Docetaxel plus S-1 versus S-1 Alone in the Treatment of Curatively Resected Stage III Gastric Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Biomarker; Therapeutic Use
- Acronyms START 2
- 06 Jun 2023 Status has been changed to discontinued, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results of 5-years follow-up data , presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 21 Jan 2023 Results (n=361) of post-hoc analysis assessing post-recurrence survival (PRS) of patients who developed recurrence during and after adjuvant chemotherapy, presented at the 2023 Gastrointestinal Cancers Symposium.